Karen Drexler
Known title: DirectorCIK: 0001504699
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
ResMed Q4 2026 Earnings Call Transcript Released. ResMed has released the transcript for its Q4 2026 earnings call, providing investors with detailed insights into the company's recent performance. This follows a quarterly earnings preview and places the stock within a broader market forecast for the mHealth sector. The release offers a factual record of management's comments on financial results and strategic direction.
Transaction History
| OM | ▲ Buy | Grant | 10,667 | $0 | 6/4/2026 | View on chart |
| OM | ▼ Sell | Open Market | 1,548 | $7K | 12/1/2025 | View on chart |
| RMD | ▲ Buy | Grant | 1,073 | $0 | 11/20/2025 | View on chart |
| OM | ▲ Buy | Grant | 8,983 | $0 | 6/2/2025 | View on chart |
| OM | ▲ Buy | Option Exercise | 31,250 | — | 3/10/2025 | View on chart |
| RMD | ▲ Buy | Grant | 1,083 | $0 | 11/20/2024 | View on chart |
| OM | ▲ Buy | Grant | 25,000 | $0 | 5/29/2024 | View on chart |
| RMD | ▼ Sell | Open Market | 425 | $91K | 4/29/2024 | View on chart |
| RMD | ▲ Buy | Grant | 884 | $0 | 11/16/2023 | View on chart |
| OM | ▲ Buy | Grant | 7,681 | $0 | 5/31/2023 | View on chart |
| RMD | ▼ Sell | Open Market | 594 | $135K | 2/2/2023 | View on chart |
| RMD | ▲ Buy | Grant | 1,122 | $0 | 11/16/2022 | View on chart |
| OM | ▲ Buy | Grant | 6,880 | $0 | 5/31/2022 | View on chart |
| RMD | ▲ Buy | Grant | 478 | $0 | 11/18/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Hims & Hers news mentioned in broader market context
Recent coverage from Yahoo discusses reasons to retain Hims & Hers stock, which shares the digital health sector with Outset Medical. While the article focuses on a different company, it highlights ongoing investor interest in the broader telehealth and digital medicine space. Outset Medical remains a high-beta stock with significant volatility, as seen in its wide 52-week range.
Hims & Hers news mentioned in broader market context. Recent coverage from Yahoo discusses reasons to retain Hims & Hers stock, which shares the digital health sector with Outset Medical. While the article focuses on a different company, it highlights ongoing investor interest in the broader telehealth and digital medicine space. Outset Medical remains a high-beta stock with significant volatility, as seen in its wide 52-week range.